VRCA News & Events

Reports 4Q revenue $5.092M, consensus $4.52M. "In 2025, Verrica successfully implemented a series of transformational changes that we believe have fundamentally improved the future growth and strategic value of our entire business," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "Our focused and efficient commercial strategy allowed us to nearly double dispensed applicator units of YCANTH from the prior year while cutting selling, general and administrative expenses by over 40% over that same period. This February, we dispensed more applicators of YCANTH per selling day than in any month in our history, reflecting strong and increasing demand for YCANTH. We are poised to advance our late-stage clinical pipeline in common warts and basal cell carcinoma, which collectively could represent a multiple billion-dollar opportunity. Finally, in 2025 we significantly improved our financial position, repaying our outstanding debt while extending our cash runway into the first quarter of 2027."

Verrica Pharmaceuticals announced the appointment of Chris Chapman as its Chief Commercial Officer. Most recently, Chapman served as Chief Commercial Officer at Dermavant Sciences

Verrica Pharmaceuticals "announced the launch of YCANTH in Japan by its partner, Torii Pharmaceutical Co. Ltd., a wholly-owned subsidiary of Shionogi & Co., Ltd., for the treatment of molluscum contagiosum. In September 2025, Verrica announced that Torii received approval from the Japanese Ministry of Health, Labour and Welfare ("MHLW") for YCANTH(R) (developed under the name TO-208) for the treatment of molluscum. Torii filed the New Drug Application for TO-208 in molluscum with MHLW in December 2024. Approval of YCANTH in Japan was based on positive top-line results from a confirmatory Phase 3 trial for the treatment of molluscum. The Phase 3 trial was conducted in Japan and was a double blind, randomized and parallel-group comparison study to evaluate the efficacy and safety of TO-208 in comparison to placebo, when applied once every 21 days for up to four applications in patients with molluscum. The top-line results from the trial showed that the proportion of subjects achieving complete clearance of all treatable molluscum lesions at the completion of the confirmatory study, the primary endpoint of efficacy, was statistically significant versus placebo. TO-208 was well tolerated during the study."